Results

Total Results: 144 records

Showing results for ""burden of illness"".

101. Health and economic outcomes of newborn screening for infantile-onset Pompe disease (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/priority-populations/richardson-et-al-2020.pdf
     January 01, 2020 - In addition to the costs of ERT, ongoing costs of care included costs of additional required medications … An ICER of $379,000/QALY is far beyond the upper bound of the unofficial range of commonly used cost-effectiveness … Inclusion of changes in quality of life for family members of a child with infantile-onset Pompe (family … year of treatment, and to stabilize the quality of life during the subsequent years of treatment;30 … the Secretary of the United States Department of Health and Human Services or of the individual members

102. Reduction in Medication Use after Bariatric Surgery (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/bariatric-surgery_research.pdf
     June 01, 2010 - Tennessee; BCBS of Hawaii; BCBS of Michigan; BCBS of North Carolina; Highmark, Inc. … (of Pennsylvania); Independence Blue Cross (of Pennsylvania); Wellmark BCBS of Iowa; and Wellmark BCBS … of South Dakota. … of the data and the accuracy of the data analysis. … time points of interest.

103. Integrating Evidence-Based Clinical and Community Strategies to Improve Health (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/tfmethods.pdf
     January 01, 2020 - the levels of nfluence and in the synthesis and integration of the vidence. … he health of the population. … Institute of Medicine. The future of the public’s health in the 21st century. … Implications of the results of community intervention trials. … Institute of Medicine. Future of the public’s health: who will keep the public healthy?

104. /docProps/thumbnail.jpeg
     cmext.ahrq.gov/confluence/download/export/downloadb6ZH1015505.zip?contentType=application/zip
     September 01, 2022 - Also need validation of assessments and other inputs to form the creation of a care plan. … of this profile MCC FHIR Care Plan Profile Relationship Diagram – The visual is a graphic example of … the constraint of this profile. … ALL Prescriptions OF ALL Clinician Visits 93% OF ALL Medicare Spending 70% 71% OF ALL Healthcare Spending … Conditions 2017 11 17% 21% 29% 32% 53% 24% 17% 6% Percent of Beneficiaries Percent of Total

105. Proceedings from AHRQ Summit on Transforming Care for People Living with Multiple Chronic Conditions (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/patient-safety/settings/mcc-summit/mcc-summit-proceedings.pdf
     October 01, 2021 - of all clinician visits, 70% of all in-patient stays, 83% of all prescriptions, 71% of all healthcare … The authors of the three evidence reviews then provided a preview of their findings of what is known … the Board of Directors of the American Association of Kidney Patients. … Knight framed the challenges of addressing the needs of PLWMCC as ones of leadership, strategy, and … The Fall 2021 publication of a special issue of Health Services Research (HSR) titled The Science of

106. Slide 1
     ecareplan.ahrq.gov/collaborate/download/temp/downloadM2Uu4142558.zip?contentType=application/zip
     May 01, 2022 - Also need validation of assessments and other inputs to form the creation of a care plan. … of this profile MCC FHIR Care Plan Profile Relationship Diagram – The visual is a graphic example of … the constraint of this profile. … ALL Prescriptions OF ALL Clinician Visits 93% OF ALL Medicare Spending 70% 71% OF ALL Healthcare Spending … Conditions 2017 11 17% 21% 29% 32% 53% 24% 17% 6% Percent of Beneficiaries Percent of Total

107. Slide 1
     ecareplan.ahrq.gov/collaborate/download/temp/downloadJhlcp223213.zip?contentType=application/zip
     May 01, 2022 - Also need validation of assessments and other inputs to form the creation of a care plan. … of this profile MCC FHIR Care Plan Profile Relationship Diagram – The visual is a graphic example of … the constraint of this profile. … ALL Prescriptions OF ALL Clinician Visits 93% OF ALL Medicare Spending 70% 71% OF ALL Healthcare Spending … Conditions 2017 11 17% 21% 29% 32% 53% 24% 17% 6% Percent of Beneficiaries Percent of Total

108. Slide 1
     ecareplan.ahrq.gov/collaborate/download/temp/downloadAZ2BG222954.zip?contentType=application/zip
     May 01, 2022 - Also need validation of assessments and other inputs to form the creation of a care plan. … of this profile MCC FHIR Care Plan Profile Relationship Diagram – The visual is a graphic example of … the constraint of this profile. … ALL Prescriptions OF ALL Clinician Visits 93% OF ALL Medicare Spending 70% 71% OF ALL Healthcare Spending … Conditions 2017 11 17% 21% 29% 32% 53% 24% 17% 6% Percent of Beneficiaries Percent of Total

109. Slide 1
     ecareplan.ahrq.gov/collaborate/download/temp/downloadVatm6143310.zip?contentType=application/zip
     May 01, 2022 - Also need validation of assessments and other inputs to form the creation of a care plan. … of this profile MCC FHIR Care Plan Profile Relationship Diagram – The visual is a graphic example of … the constraint of this profile. … ALL Prescriptions OF ALL Clinician Visits 93% OF ALL Medicare Spending 70% 71% OF ALL Healthcare Spending … Conditions 2017 11 17% 21% 29% 32% 53% 24% 17% 6% Percent of Beneficiaries Percent of Total

110. Final Progress Report: Risk of Acute Asthma Associated with the Pediatric Use of Opioids (pdf file)
     ce.effectivehealthcare.ahrq.gov/sites/default/files/2024-02/chen-report.pdf
     January 01, 2024 - Final Progress Report: Risk of Acute Asthma Associated with the Pediatric Use of Opioids … FINAL PROGRESS REPORT Risk of Acute Asthma Associated with the Pediatric Use of Opioids … of Houston College of Pharmacy, Houston, Texas 2Department of Pediatrics, Section of Pulmonology, … , affecting 8.7% of the children under 18 years of age and 10.2% of the older teens aged 15-19 years … use of these medications for a period of 1 year.

111. Development of a Primary Care Guie for Implementing Evidence-Based Screening and Counseling for Unhealthy Alcohol Use With Epic-Based Electronic Health Record Tools: A Pilot Dissemination Project (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-research-report-unhealthy-alcohol-use-final.pdf
     September 01, 2018 - Therefore, no statement in this report should be construed as an official position of AHRQ or of the … Key Informants are not involved in the analysis of the evidence or the writing of the report. … power of story as well as data • Frequent and early small tests of change • Transparency of data … School of Medicine. Division of General Medicine & Clinical Epidemiology. … Please rate the usefulness of each of the sections below, on a scale of 1 to 4, where 1 = very useful

112. Health and economic outcomes of newborn screening for infantile-onset Pompe disease (pdf file)
     ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/priority-populations/richardson-et-al-2020.pdf
     January 01, 2020 - In addition to the costs of ERT, ongoing costs of care included costs of additional required medications … An ICER of $379,000/QALY is far beyond the upper bound of the unofficial range of commonly used cost-effectiveness … Inclusion of changes in quality of life for family members of a child with infantile-onset Pompe (family … year of treatment, and to stabilize the quality of life during the subsequent years of treatment;30 … the Secretary of the United States Department of Health and Human Services or of the individual members

113. A Severity-of-Illness Classificiation for Mental and Substance-Use Disorders for Use With Hospital Administrative Data
     hcup-us.ahrq.gov/reports/SOI.jsp
     June 01, 2016 - , 2002 Table 3: Odds of utilization of ED and IP services for M/SU-related expected functioning of … of mobility, inability to carry out activities of daily living). … The categorization of severity-of-illness in terms of functioning enhanced these predictions beyond the … Table 3: Odds of utilization of ED and IP services for M/SU-related expected functioning of moderate … Number of Beds 1.699** 1.556* 2.186** 2.077** 1.598* 1.553 Log of Number of Chemical

114. Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease (pdf file)
     www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-135-fullreport.pdf
     February 01, 2017 - Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease Timeliness of Antibiotic … Include results of all tests of validity and reliability, including description(s) of the study sample … maximum of 9). … of this process. … the focus of 20 the measure, scientific soundness of the measure, identification of disparities

115. Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease (pdf file)
     www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-135-fullreport.pdf
     February 01, 2017 - Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease Timeliness of Antibiotic … Include results of all tests of validity and reliability, including description(s) of the study sample … maximum of 9). … of this process. … the focus of 20 the measure, scientific soundness of the measure, identification of disparities

116. Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease (pdf file)
     www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-135-fullreport.pdf
     February 01, 2017 - Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease Timeliness of Antibiotic … Include results of all tests of validity and reliability, including description(s) of the study sample … maximum of 9). … of this process. … the focus of 20 the measure, scientific soundness of the measure, identification of disparities

117. Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease (pdf file)
     www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-135-fullreport.pdf
     February 01, 2017 - Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease Timeliness of Antibiotic … Include results of all tests of validity and reliability, including description(s) of the study sample … maximum of 9). … of this process. … the focus of 20 the measure, scientific soundness of the measure, identification of disparities

118. Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease (pdf file)
     www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-135-fullreport.pdf
     February 01, 2017 - Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease Timeliness of Antibiotic … Include results of all tests of validity and reliability, including description(s) of the study sample … maximum of 9). … of this process. … the focus of 20 the measure, scientific soundness of the measure, identification of disparities

119. Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease (pdf file)
     www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-135-fullreport.pdf
     February 01, 2017 - Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease Timeliness of Antibiotic … Include results of all tests of validity and reliability, including description(s) of the study sample … maximum of 9). … of this process. … the focus of 20 the measure, scientific soundness of the measure, identification of disparities

120. Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease (pdf file)
     ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-135-fullreport.pdf
     February 01, 2017 - Timeliness of Antibiotic Prophylaxis for Children With Sickle Cell Disease Timeliness of Antibiotic … Include results of all tests of validity and reliability, including description(s) of the study sample … maximum of 9). … of this process. … the focus of 20 the measure, scientific soundness of the measure, identification of disparities